日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer

VIKTORIA-1试验:Gedatolisib联合Fulvestrant,加或不加Palbociclib治疗激素受体阳性/HER2-/PIK3CA野生型晚期乳腺癌

Hurvitz, Sara A; Layman, Rachel M; Curigliano, Giuseppe; André, Fabrice; Cristofanilli, Massimo; Kim, Sung-Bae; Martínez Rodríguez, Jorge Luis; Nadal, Jorge C; Kim, Gun Min; Lo, Louisa; Remolina-Bonilla, Yuly A; Rosselli, Geronimo; Emile, George; Korbenfeld, Ernesto; Puig, Juan Manuel; Wesolowski, Robert; Martin, Miguel; Ring, Alistair; Han, Hyo S; Giordano, Antonio; Mutka, Sarah C; Moss, Keren; Suzuki, Sam; Sullivan, Brian; Gorbatchevsky, Igor; Pistilli, Barbara

Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

格达托利西布联合帕博西尼和来曲唑治疗既往未接受过全身治疗的激素受体阳性、HER2阴性晚期乳腺癌患者

Wesolowski, Robert; Rugo, Hope S; Specht, Jennifer M; Han, Hyo S; Kabos, Peter; Vaishampayan, Ulka; Wander, Seth A; Gogineni, Keerthi; Spira, Alexander; Schott, Anne F; Abu-Khalaf, Maysa; Mutka, Sarah C; Suzuki, Samuel; Sullivan, Brian; Gorbatchevsky, Igor; Layman, Rachel M

Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma

copanlisib(一种 PI3K 抑制剂)治疗复发或难治性、惰性或侵袭性淋巴瘤的 II 期研究

Dreyling, M; Morschhauser, F; Bouabdallah, K; Bron, D; Cunningham, D; Assouline, S E; Verhoef, G; Linton, K; Thieblemont, C; Vitolo, U; Hiemeyer, F; Giurescu, M; Garcia-Vargas, J; Gorbatchevsky, I; Liu, L; Koechert, K; Peña, C; Neves, M; Childs, B H; Zinzani, P L